Author Archives: admin


Stem Cell Clinic > Articles by: admin

Down syndrome organoids give insights into Alzheimer’s disease – BioWorld Online

By Induced Pluripotent Stem Cells

LONDON New human brain organoids that precisely model the three hallmarks of Alzheimers disease amyloid plaque-like lesions, progressive neuronal death and abnormal accumulations of tau are now ready to be developed for use in high-throughput drug screening.

At the same time, the organoids have led to the discovery that the BACE2 (beta amyloid precursor protein cleaving enzyme) gene can act as a natural suppressor of Alzheimers pathology. The finding points to a possible reason why BACE1 inhibitors have failed to show protective effects in clinical trials, since those drugs also block the effects of BACE2.

The Alzheimers-like pathology is seen in cerebral organoids derived from hair donated by people with Down syndrome, or trisomy 21, who, because they carry an extra copy of the beta-amyloid precursor protein (APP) gene, have a very high risk of developing Alzheimers disease.

In the study, published in the July 10, 2020, online issue of Molecular Psychiatry, group leader Dean Nizetic, professor of cellular and molecular biology at Queen Mary University of London, and national and international collaborators, reprogrammed hair cells to induced pluripotent stem cells (iPSCs) and then prompted them to become brain organoids.

Those organoids, containing markers of all six layers of the human cortex, rapidly developed Alzheimers-like pathology.

While there are other cell model systems of Alzheimers brain pathology, they are based on promoting overexpression of introduced genes. This work represents a remarkable achievement, as this is the first cell-based system that has the full trio of Alzheimers pathologies, without any artificial gene overexpression, Nizetic said. This system opens up the prospect for screening for new drugs aimed at delaying or even preventing Alzheimers before neuronal death starts.

It was very surprising to find all three hallmarks of Alzheimers disease in the organoids, Nizetic said. It has been shown that brain organoids are relevant to the study of neurodevelopmental disorders, but it was thought they were not suitable for neurodegeneration studies, he told BioWorld.

Getting to the BACE of things

Despite having three copies of the APP gene, around 30% of people with Down syndrome do not develop Alzheimers disease by the age of 60, suggesting that some of the other 400 or so genes on chromosome 21 have a protective effect.

One of the genes on chromosome 21 is BACE2, the homologue of BACE1. As the main beta secretase gene cleaving APP in the brain, BACE1 is a major drug target in Alzheimers disease. BACE2 is found in the brain, but its function is less clear, with evidence of both pro- and anti-amyloidogenic activity.

Profiling non-amyloidogenic peptides that had the signature of BACE2 cleavage in Down syndrome organoids, compared to organoids derived from normal, disomy 21 donors, showed average levels of those peptides were doubled in trisomy 21.

That result was reproduced in three separate experiments, starting from undifferentiated induced pluripotent stem cells (iPSCs) from different individuals.

However, looking at an organoid from a sporadic case of Alzheimers disease caused by an extra copy of the APP gene, in an individual who was otherwise disomic, the researchers found the non-amyloidogenic peptide profile was similar to normal controls.

The researchers concluded that a third copy of a gene other than APP was behind those peptide profiles, and they said, BACE2 is the gene in question.

To assess if that might have any relevance in vivo, they compared the peptide profile from the trisomy organoids with those found in cerebrospinal fluid of people with Down syndrome, and to controls. They found similar increases in BACE2 cleaved peptides in the fluid samples, validating the observations made in the organoids.

The researchers next designed an assay to see if BACE1 inhibitors that have been tested in clinical trials in Alzheimers block the beta-amyloid degrading activity of BACE2. They found two BACE1 inhibitors had that effect.

Its not the only reason, but BACE2 inhibition could have been confounding clinical trials [of BACE1] inhibitors, Nizetic said. That should be taken into consideration when designing new BACE1 inhibitors, he said.

As Nizetic acknowledged, the findings rest on a very small number of Down syndrome organoids from seven donors. Interestingly, two of those did not show any changes in BACE2 cleaved peptides. One was from a 37-year-old man with Down syndrome, who unlike the rest of the cohort did not have a clinical diagnosis of Alzheimers disease. The other was from an anonymous donor whose medical history is not known.

Using CRISPR/Cas9, the researchers edited out a single copy of the BACE2 gene in iPSCs from the unaffected donor, maintaining the trisomy of the rest of chromosome 21. The resulting organoids showed a 27% to 34 % reduction in BACE2 activity compared to an unedited trisomy 21 control, and no significant differences in activity compared to a normal control.

Notably, eliminating the third copy of the BACE2 gene caused the brain organoids derived from the unaffected Down syndrome donor to develop extremely early Alzheimers plaque-like deposits. Those progressed at pace, becoming much denser by day 96, with associated massive cell death.

This pinpoints triplication of BACE2 as a likely cause of specific anti-amyloidogenic trisomy 21 effects, the researchers said. It appears that reducing BACE2 by a third tips the balance against anti-amyloidogenic activity and provokes Alzheimers-like pathology.

The drug screening application opens up immediately, once we scale-up, speed-up and do some refinements, Nizetic said. Discussions with potential commercialization partners are underway.

In addition, the brain organoids could form the basis of biomarkers for detecting people at risk of developing Alzheimers disease, well before there are any symptoms.

The organoids also provide the means to discover other natural suppressor genes of neurodegenerative diseases.

Taken overall, the researchers said the data prove the physiological role of BACE2 as a dose-sensitive Alzheimers disease suppressor gene. That potentially explains the delay in developing Alzheimers disease in 30% of people with Down syndrome.

The rest is here:
Down syndrome organoids give insights into Alzheimer's disease - BioWorld Online

Lingering Questions Limit Impact of MRD in the Clinic Despite Its Growing Prominence – AJMC.com Managed Markets Network

By Stem Cell Treatment

While minimal residual disease has become an important way to track how patients respond to therapies for multiple myeloma, the treatment implications of the metric are not yet clear, according to a review article.

Investigators, including corresponding author Roberto Mina, MD, of the University of Torino, in Italy, analyzed the latest research on MRD as a clinical tool in a review article published in the Journal of Clinical Medicine.1

Mina and colleagues began by pointing out that new therapeutic options for patients with MM have significantly increased rates of complete remission (CR) among patients with MM, which in turn has led to longer rates of progression-free survival (PFS) and overall survival (OS).

It is now clear that the real prognostic value of CR relies on the absence of minimal residual disease (MRD), the authors said. After the International Myeloma Working Group (IMWG) updated the response criteria in 2016 to incorporate assessments of MRD inside and outside of the bone marrow, interest in MRD as a surrogate endpoint for survival outcomes has increased, Mina and colleagues wrote.

After outlining methods of assessing MRD, the investigators explained its limits in the clinic, arguing that theres no current evidence supporting the idea that MRD can be used to drive decision-making in a clinical setting.

One question still unanswered is whether, in an era of highly effective induction regimens, MRD status might be used as a way to choose between transplant- and non-transplant-based treatment. Studies have shown high MRD-negativity rates both in patients who underwent high-dose melphalan2 with autologous stem-cell transplantation (HDM-ASCT) and those who did not.3

Altogether, these data suggest the hypothesis that patients who are able to achieve MRD negativity with the induction therapy may not need HDM-ASCT, thus supporting the development of controlled trials randomizing patients to ASCT vs. non-transplant-based strategies, they wrote.

Another question is how long, if at all, maintenance therapy is needed in MRD-negative patients following induction therapy and HDM-ASCT. Mina and colleagues said theres insufficient data to justify removal of maintenance therapy.

On the basis of the data generated so far, it is not yet possible to advise against maintenance therapy for patients who are MRD negative after ASCT or to encourage treatment discontinuation for those patients who become MRD negative during maintenance, they said.

Mina and colleagues also discussed the frequency of MRD testing. They said it makes sense to monitor MRD status over time, since an MRD-positive patient can become MRD-negative during treatment, but the opposite can also happen. Such negative-to-positive reversals can be a sign of pending relapse.

From a clinical perspective, these data could help clinicians restart treatment before the occurrence of clinical relapse, thus preventing the morbidity associated to MM proliferation, they wrote.

One final question, the authors said is whether patients who are MRD-positive after HDM-ASCT or consolidation might benefit from switching to non-cross-resistant drugs or from treatment intensification, in order to maximize the odds of achieving MRD negativity, particularly in light of the promising results obtained with immunotherapeutic strategies tested in the relapse setting. That question, too, remains unanswered.

In conclusion, the investigators said that while there are a number of intriguing possibilities as a result of MRD assessment, there also remain a number of key questions that must be resolved before MRD reaches its full clinical potential.

MRD-based clinical trials and their results are eagerly needed to fully understand the value of MRD testing in MM and to demonstrate the validity of using MRD as the main driver of clinical decisions, both in the upfront and relapsed settings, they said.

References:

More here:
Lingering Questions Limit Impact of MRD in the Clinic Despite Its Growing Prominence - AJMC.com Managed Markets Network

Restorative therapies for erectile dysfunction: Where are we at in 2020? – Urology Times

By Stem Cell Medicine

Restorative therapies are an exciting area of potential treatments for patients with erectile dysfunction (ED); however, there is a paucity of clinical data regarding their efficacy and safety, according to Trinity Bivalacqua, MD, PhD.1

The goal of restorative therapies in ED is to reestablish whole-organ function and reverse penile dysfunction using regenerative medicine technology, Bivalacqua explained in a presentation during the 2020 AUA Virtual Experience. The restorative therapies for ED include platelet rich plasma (PRP), stromal vascular fraction (SVF), amniotic fluid (AF), and stem cells (mesenchymal cells, adipose derived stem cells, amniotic stem cells, and cord blood stem cells).

Restorative therapies are particularly relevant for patients who have had radical prostatectomies and have post-prostectomy ED, as well as for patients with severe ED as it relates to peripheral vascular disease and diabetes, said Bivalacqua, director of Urologic Oncology at Johns Hopkins Univsersity.

Although the potential of restorative therapy to treat ED itself, and not just its symptoms, has created a lot of buzz in the urology community, Bivalacqua said the lack of data in the literature backing the efficacy and safety of the technology means it should currently be reserved for clinical trials. Accordingly, this is the current position of the Sexual Medicine Society of North America (SMSNA), which sponsored Bivalacquas discussion:

Given the lack of regulatory agency approval for any restorative (regenerative) therapies for the treatment of ED and until such time as approval is granted, SMSNA believes that the use of shock waves or stem cells or platelet rich plasma is experimental and should be conducted under research protocols (clinical trials) in compliance with Institutional Review Board approval.

In his discussion during the AUA online platform, Bivalacqua discussed the limited available evidence in the literature for each ED-focused restorative therapy and the next steps for this technology.

PRP is the most common restorative therapy used for ED. This treatment can be applied through intracavernous injection. Although he did not make a recommendation for its use outside of clinical trials, Bivalacqua said PRP Falls under the HCT/P 361 exemption proposed by the FDA. This means in clinical practice you can usePRPwithout gaining FDA approval. As long as the tissue/biospecimen is not manipulated once its removed from the patient, it is then exempt from FDA approval and clinical trials.

With PRP, a clinician can use a normal centrifuge to isolate the PRP, which can then be injected. It does not have a specific CPT billing code, but can be categorized under a nonspecific code for blood transfusion and reinfection. For the most part, it is not covered by insurance or Medicare, with the post common payment form being cash, said Bivalacqua. Regarding clinical evidence, there have been no randomized clinical trials of PRP.

Bivalacqua said there is 1 peer-reviewed trial2 of PRP in the literature, but it only had safety results. The study assessed PRP in 17 patients with various urological diseases, including 4 patients with ED. The results showed that PRP injections were safe overall, with some mild bruising, but no serious adverse events.

Autologous SVF involves the removal of adipose tissues, often through liposuction. The removed tissues are then separated into individual components, with the key components, such as adipose-derived stemcells(ADSCs)and endothelial precursorcells(EPCs), being reinjected into the patient. ADSCs and EPCs release beneficial cytokines and growth hormones, which promote tissue survival, angiogenesis, and further stem cell recruitment, said Bivalacqua.

Since SVF involves the patient specimens being manipulated, unlike with PRP, this procedure does not fall under the FDA HCT/P 361 exemption and no SVF devices are currently FDA approved. There is also no clinical trial data in the literature supporting the efficacy of SVF.

Some trials have been published showing promise for low-intensity shockwave therapy as a treatment for patients with ED. One study3 looked at the long-term efficacy of low-intensity shockwave therapy using an electrohydraulic device in 156 patients who initially had a successful outcome according to the minimal clinically important difference on the International Index of Erectile Function-Erectile Function (IIEF-EF). Patients were assessed per the IIEF-EF at 6, 12, 18, and 24 months.

Although the treatment was successful in 63.5% (n = 99) of patients at 1 month after treatment, efficacy gradually decreased over time. Among the 99 patients who initially responded, only 53 (53.5%) were still experiencing a beneficial treatment effect at 2 years follow-up.

They found that there was very little durability of the shock-wave therapy in patients with severe ED. Whatever effect was seen was then mitigated at 24 months, said Bivalacqua. Those patients with non-severe EDthose who would typically respond to PDE-5 inhibitorshad a more efficacious response.

Another study4 of low-intensity shockwave therapy used an electromagnetic device to treat patients with ED. There were 87 evaluable patients who were randomized to receive 1 of 2 shockwave regimens: Group A (n= 45) received 3600 shocks (720/day) over 5 days and Group B (n = 42) received 3600 shocks over 2 weeks (600 over 3 days each week). The was a statistically significant improvement in IIEF-EF score for both groups, with a mean increase of 2.7 in both group A and group B (P <.05). There was also a statistically significant improvement in Erectile Hardness Scale score in both arms at 0.6 points in group A and 0.5 points in group B.

Although the improvements were statistically significant, the benefits were minor, leaving Bivalacqua to ask, The question is, Is this clinically significant? My perspective on this is that this did not include a sham group and the improvement was in patients who were typically PDE-5inhibitorresponders. But I do think we have to acknowledge that using the electromagnetic probe, which causes a lower peak energy, may be safer for patients.

While it is an exciting field, Bivalacqua noted that there is an ugly side to restorative therapies for ED

The global use of PRP, especially in North America, is very high, despite the lack of any clinical evidence that it is effective or safe, said Bivalacqua, adding, Some practitioners are cashing in on the hype of shockwave therapy even though the treatments are not FDA approved.

To combat these issues, Bivalacqua said several questions need to be answered in the literature. The next steps with restorative therapies are determining optimal dosing regimens; assessing the total power and number of shocks with shockwave devices; determining the optimal device choiceelectromagnetic versus electrohydraulic; and evaluating the duration of studies and role of maintenance therapy. But more importantly, we need to have a sham in randomized controlled trials.

Bivalacqua also provided several suggestions on how the efficacy of the available restorative therapies could be improved.

The future is combination therapy, where we include low-intensity shockwave therapy with the injection of either SVF or stem cells. And we have to include a maintenance phase. Other protein- and gene-based therapies, such as SDF-1, which hone stem cells, are obviously an important next step. And neurotrophic factors placed at the time of radical prostatectomy are the only way that we are going to be able to regenerate nerves post prostatectomy.

References

1. Bivalacqua T. State-of-the-Art Lecture: Update on Clinical Trials on Restorative Therapies for Erectile Dysfunction. Presented during 2020 AUA Virtual Experience. June 27-28, 2020.

2. Matz EL, Pearlman AM, Terlecki RP, et al. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018;59(1):61-65. doi: 10.4111/icu.2018.59.1.61

3. Kitrey ND, Vardi Y, Appel B, et al. Low intensity shock wave treatment for erectile dysfunction-how long does the effect last? J Urol 2018;200(1):167-170.doi: 10.1016/j.juro.2018.02.070

4. Patel P, Katz J, Lokeshwar SD, et al. Phase II randomized, clinical trial evaluating 2 schedules of low-intensity shockwave therapy for the treatment of erectile dysfunction. Sex Med. 2020 Jun; 8(2): 214222. doi: 10.1016/j.esxm.2020.01.010

See more here:
Restorative therapies for erectile dysfunction: Where are we at in 2020? - Urology Times

Local scientists create ‘mini livers’ to trial therapies for liver diseases – The Straits Times

By Adult Stem Cells

Local scientists here have successfully created human liver organoids, or "mini livers", to help them develop and trial therapies for various liver diseases.

This is part of a research collaboration between the Agency for Science, Technology and Research's Genome Institute of Singapore (GIS) and the National University of Singapore (NUS). The liver organoids, each with a diameter of around 0.5mm, are able to capture the functional and structural features of the human liver.

Cultivated in vitro in a petri dish, the organoids are grown outside the body from stem cells, which are initially reprogrammed from human skin cells over a three-month period.

To better understand the effects of non-alcoholic fatty liver disease (NAFLD) on the organ, the liver organoid cells are supplemented with a fatty acid-rich nutrient, to replicate the effect of high carbohydrate and fatty food intake, which is said to be the primary cause of the disease.

Characterised by the building up of fat in the livers of people who consume little to no alcohol, the disease is often associated with obesity and Type 2 diabetes, affecting up to a third of the local adult population.

When fatty food is consumed, hepatocytes, which make up around 80 per cent of the cells within the liver, help to store and process excess fats.

Cholesterol from these fats are then secreted into liver canals known as the bile canaliculi, before reaching the gastrointestinal system where it is absorbed into the blood.

However, too much fat being accumulated in the liver may result in disruptions to the structure and function of the hepatocyte cells, while the bile canaliculi may end up being shortened or diminished.

When combined, this could lead to liver injury, eventually hampering the organ's function over time.

In more severe cases, the disease could lead to liver cancer and liver cirrhosis, where the liver no longer functions properly, owing to long-term damage.

Liver organoids developing in a dish (far left) and a visualisation of different cell types and liver structures in the organoids, including hepatocyte cells and bile canaliculi (both in green). PHOTO: GENOME INSTITUTE OF SINGAPORE

Associate Professor Dan Yock Young of NUS' Yong Loo Lin School of Medicine said: "Patients with early stage NAFLD remain largely asymptomatic, and the disease progresses silently over the years.

"What drives the disease progression and liver injury remains largely unknown. The development of advanced human liver models of the disease will provide a critical tool for researchers to identify molecular drivers of the disease."

Through the liver organoid model, scientists can observe and capture molecular and structural changes of the liver as the disease progresses - all within the course of a week.

In addition, the organoid model could also serve as a useful tool for drug testing and screening, given that there are currently no approved therapies for NAFLD.

As the disease is closely associated with obesity, the treatment recommendations for patients with liver disease are often dietary and lifestyle changes.

Professor Ng Huck Hui, senior group leader at GIS, said: "The increase in prevalence of liver disease and the lack of therapeutics place a huge burden on healthcare systems worldwide.

"There is a dire need to better understand liver biology in order to develop advanced cellular models of disease, and novel therapies."

Follow this link:
Local scientists create 'mini livers' to trial therapies for liver diseases - The Straits Times

Out-of-Pocket Costs Often Higher Than Expected for Patients with Cancer Participating on Clinical Trials – Curetoday.com

By Stem Cell Doctors

According to the lead study investigator, work needs to be done to ensure financial toxicity is not a deterrent to clinical trial enrollment and that trial sponsors and payers should consider trial expense reimbursement.

Clinical trials have additional visits and costs compared to the standard of care, Dr. Ryan W. Huey, an assistant professor in the department of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center in Houston, said during a pre-recorded presentation of the data. And while financial toxicity has been well described for patients with cancer, it is less well established for patients who enroll in clinical trials.

To evaluate financial toxicity, which is the direct and indirect impact of health care costs that lead to significant financial burden, and out of-of-pocket costs for patients with cancer enrolled in early phase clinical trials, Huey and colleagues surveyed patients who were on a trial for more than a month. The goal, Huey said during the presentation, was to talk to patients who accurately understood what their monthly expenses were while on their respective trial.

The researchers collected data regarding patient demographics, including, but not limited to, patient and disease characteristics, as well as insurance status.

Using the 12-question COmprehensive Score for Financial Toxicity (COST)Functional Assessment of Chronic Illness Therapy (FACIT) survey, the researchers assessed the financial toxicity that 213 patients (with a median age of 59 years) in early-phase clinical trials experienced. More than half of the trial participants surveyed were female (59%) and more than three-fourths (79%) were non-Hispanic white. Other characteristics patients were grouped by included yearly household income, type of insurance, employment status and length of time spent on current trial.

More than half of the participants (55%) had employer-provided insurance, 38% had Medicare, 11% had personally purchased insurance and the remaining participants had either Medicaid (2%), VA-provided insurance (4%), personally purchased supplemental insurance (9%) or other (1%).

Forty percent of the patients were employed either full- or part-time, while 37% were retired and 15% were unemployed.

Half of the participants traveled more than 300 miles to receive their cancer care. The other half either traveled less than 100 miles (23%) for their cancer care or traveled 101 to 300 miles (27%).

Thirty percent of the participants were either fully (6%) or partially (24%) reimbursed for their travel.

Out-of-pocket, patients spent a median of $1,075 a month on non-medical expenses. Expenses attributed to medical costs accounted for $475 out-of-pocket per month. The survey demonstrated that more than half (55%) of patients felt that their expenses attributed to medical costs were higher than expected. Sixty-four percent of patients also reported that they felt their non-medical expenses were higher than expected.

Factors associated with a worse financial burden included an annual household income of less than $60,000, participating on at least one previous phase 1 clinical trial and living more than 100 miles away from the clinical trial site.

Huey concluded his presentation noting that the economic burden patients participating on clinical trials experience is high, and that most of the costs are related to nonmedical expenses.

Financial toxicity disproportionately affects patients with lower income and those who travel far to receive their care, he said. And costs are often higher than expected. Work needs to be done to ensure this financial toxicity is not a deterrent to enrollment. And sponsors and payers should consider the role of trial expense reimbursement.

Visit link:
Out-of-Pocket Costs Often Higher Than Expected for Patients with Cancer Participating on Clinical Trials - Curetoday.com

Cancer Stem Cells (Cscs) Market Breaking new Grounds and touch new Level in Upcoming Year by Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell,…

By Stem Cell Treatment

Cancer Stem Cells Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Cancer Stem Cells Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get Free Sample Copy of This Report:

https://www.theresearchinsights.com/request_sample.php?id=111983

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in This Report:

Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, Aviva Biosciences Corporation, ScreenCell, Silicon Biosystems.

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Cancer Stem Cells market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Cancer Stem Cells markets trajectory between forecast periods.

Global Cancer Stem Cells Market Segmentation:

Market Segmentation: By Type

CellSearch Others

Market Segmentation: By Application

Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment

Get Upto 30% Discount on this Report:

https://www.theresearchinsights.com/ask_for_discount.php?id=111983

Reasons for buying this report:

Table of Contents

Global Cancer Stem Cells Market Research Report 2020 2026

Chapter 1 Cancer Stem Cells Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cancer Stem Cells Market Forecast

If You Have Any Query, Ask Our Experts:

https://www.theresearchinsights.com/enquiry_before_buying.php?id=111983

If you have any special requirements, please let us know and we will offer you the report as you want.

Read more:
Cancer Stem Cells (Cscs) Market Breaking new Grounds and touch new Level in Upcoming Year by Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell,...

Stem Cell Therapy Market Key Opportunities & Development the COVID-19 – Kentucky Journal 24

By Stem Cell Medicine

Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.

The global stem cell therapy market is categorized based on various modes of treatment and by therapeutic applications. The treatment segment is further sub-segmented into autologous stem cell therapy and allogeneic stem cell therapy. The application segment includes metabolic diseases, eye diseases, immune system diseases, musculoskeletal disorders, central nervous system disorders, cardiovascular diseases and wounds and injuries.

Request For Report Sample:http://marketgrowthanalysis.com/reports/sample/217

Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell Therapy Autologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

Hospitals Ambulatory Surgical Centers

Stem Cell Therapy Market, By Application:

Oncology Central Nervous System Diseases Eye Diseases Musculoskeletal Diseases Wound & Injuries Metabolic Disorders Cardiovascular Disorders Immune System Disorders

Request For COVID-19 Analysis:http://marketgrowthanalysis.com/reports/enquiry/217

Stem Cell Therapy Market, By Geography:

North America Europe Asia Pacific Middle East & Africa Latin America

In terms of geographic, North America dominates the global stem cell therapy market due to increased research activities on stem cells. The U.S. represents the largest market for stem cell therapy followed by Canada in North America. However, Asia is expected to show high growth rates in the next five years in global stem cell therapy market due to increasing population. In addition, increasing government support by providing funds is also supporting in growth of the stem cell therapy market in Asia. China and India are expected to be the fastest growing stem cell therapy markets in Asia.

Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are: Gamida Cell ReNeuron Group, plc Osiris Therapeutics, Inc. Stem Cells, Inc. Vericel Corporation. Mesoblast, Ltd.

Request For Report TOC:http://marketgrowthanalysis.com/reports/toc/217

Follow this link:
Stem Cell Therapy Market Key Opportunities & Development the COVID-19 - Kentucky Journal 24

Comprehensive Study on Regenerative Medicine Market 2020 | Trends, Drivers, Strategies, Applications and Competitive Landscape Forecast to 2024 – Cole…

By Stem Cell Medicine

Becton Dickinson and Company

Scope of the Report:

As per the , regenerative medicines are used to repair, replace, and regenerate the tissues and organs affected by injury, disease, or the natural aging process. These medicines restore the functionality of cells and tissues and are used in several degenerative disorders, such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications.

The Report Covers:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14244620

Key Market Trends:

Dermatology is the Segment by Application that is Expected to be the Largest During the Forecast Period

Dermatology is estimated to have the largest share in revenue generation, and this high contribution is attributive to the presence of easy grafting techniques for dermatological wounds and diseases. Skin, being an organ with great cell replication characteristics, provides various types of stem cells from its different layers. Therefore, there are a broad range of products present, from patches to cure small injuries to matrix and grafts for chronic wounds and burns. Thus, the segment is expected to continue to dominate the market through to the forecast period.

The increasing number of accidents and bone defects is also expected to drive the regenerative medicine market. There are also several research studies that are being conducted on tissue engineering for the development of bone graft substitutes, with the help of regenerative medicine. So, with the new advances in bone graft, the market is expected to grow over the forecast period.

North America Holds the Largest Share and is Expected to Follow the Same Trend Over the Forecast Period

North America is estimated to have the largest share, in terms of revenue, owing to the presence of major players and rapid advances in technology, along with high investments in stem cell and oncology research. There is also an increasing prevalence of diseases, such as cancer and diabetes, which can now be cured by various stem cell therapies. Additionally, the awareness regarding the available stem cell procedures and therapies among people is rising, which in turn, is increasing the demand for the overall market.

Key Questions Answered in This Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14244620

Detailed TOC of Regenerative Medicine Market 2019-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Adoption of Stem Cell Technology 4.2.2 Technological Advancements in Regenerative Medicine 4.3 Market Restraints 4.3.1 Regulatory and Ethical Issues 4.3.2 High Cost of Treatments 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Type of Technology 5.1.1 Stem Cell Therapy 5.1.2 Biomaterial 5.1.3 Tissue Engineering 5.1.4 Other Types of Technologies 5.2 By Application 5.2.1 Bone Graft Substitutes 5.2.2 Osteoarticular Diseases 5.2.3 Dermatology 5.2.4 Cardiovascular 5.2.5 Central Nervous System 5.2.6 Other Applications 5.3 Geography 5.3.1 North America 5.3.1.1 United States 5.3.1.2 Canada 5.3.1.3 Mexico 5.3.2 Europe 5.3.2.1 Germany 5.3.2.2 United Kingdom 5.3.2.3 France 5.3.2.4 Italy 5.3.2.5 Spain 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.1 China 5.3.3.2 Japan 5.3.3.3 India 5.3.3.4 Australia 5.3.3.5 South Korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East & Africa 5.3.4.1 GCC 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East & Africa 5.3.5 South America 5.3.5.1 Brazil 5.3.5.2 Argentina 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Allergan 6.1.2 Osiris Therapeutics 6.1.3 Integra Lifesciences 6.1.4 Cook Biotech Incorporated 6.1.5 Organogenesis Inc. 6.1.6 Baxter 6.1.7 Medtronic 6.1.8 Thermo Fisher Scientific 6.1.9 Sigma-Aldrich Co. 6.1.10 Becton Dickinson and Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Cable Conduits Market Size by Top Key Players 2020 Global Growth Rate by Share, Industry Segment, Future Prospect, Key Finding and Market Dynamics Forecast to 2026

Insulated Concrete Form Market Size Report Forecast 2020 2024 Business Revenue, Opportunities, Future Growth, Trends Plans, Top Key Players, Global Analysis by Share

Microwavable Food Market Growth Size, Share 2020 | Industry Analysis with COVID-19 Impact, Company Overview, Key Countries with Future Prospect to 2026

Aircraft Wire and Cable Market Size, Trends 2020 Global Industry by Manufacturers Growth Rate | COVID-19 Impact on Future Scope, Demand Status, Business Strategy Forecast to 2026

Aspheric Lens Market Size, Trends 2020 Global Industry by Manufacturers Growth Rate | COVID-19 Impact on Future Scope, Demand Status, Business Strategy Forecast to 2026

Read more:
Comprehensive Study on Regenerative Medicine Market 2020 | Trends, Drivers, Strategies, Applications and Competitive Landscape Forecast to 2024 - Cole...

Biobanks Market Research Report 2020-2024 | Analysis by Key Regions, Manufacturing Technology and Development Forecast Industry Research.co – 3rd…

By Stem Cell Medicine

VWR International LLC

Biobanks Market Report Highlights:

Scope of the Report:

As per the , biobank is a biorepository, where various biomaterials (usually human specimens) are stored for research purpose. This study targets gaining a detailed overview of the market dynamics of the contemporary biobank market during the forecast period. It focuses on the need to develop strategic insights into the global and country-level markets, taking into consideration the demand for services and equipment in biobanks. The growth of this market is largely fueled by the increasing applications, increasing investments in R&D, technological advancements, and growing demand in the developing countries (China and India) of Asia-Pacific.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999520

Key Market Trends:

Cryogenic Storage Segment by Equipment is Expected to Account for the Largest Market Share During the Forecast Period

In biobanks, the cryogenic storage systems are basically used to store different life sciences materials at a very low temperature. The low temperature storage increases the longevity of the cells, while at the same time reducing the intensity of freezing damage. Various cryogenic storage devices are available that have been designed to allow storage of both liquid and vapor phase materials. The temperature in the cryogenic storage system is required to be maintained continuously. Currently, all demand is for automated cryogenic storage devices. This segment is further divided into refrigerators, ice machines, and freezers. With advanced storage and automated devices propelling the growth of the market, steady growth in the North American and European markets is expected.

North America Accounted for the Largest Share in the Global Market

North America is holds a major share in the global biobanks market, and it is expected to show a similar trend over the forecast period, without significant fluctuations. The United States has the largest expenditure for R&D and better healthcare infrastructure in the world. Different pharmaceutical/ biotech companies, academia, and research institutes are utilizing biobanks for the storage of DNA, RNA, tissue, serum, blood, plasma, cells, etc. According to the Hastings Center, a non-profit organization, 300 million biospecimens have been stored in the United States in various public and private biobanks. The market is in demand for the most advanced automated systems, and there is also a high adoption rate for new technology.

The Report Covers:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999520

Detailed TOC of Biobanks Market Report 2019-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Innovations in Regenerative Medicine 4.2.2 Growing Incidences of Chronic Diseases 4.2.3 Advances in Drug Discovery and Development 4.2.4 R&D Funding and Investments by Government and Non-governmental Organizations 4.3 Market Restraints 4.3.1 Regulatory Issues 4.3.2 Cost Constraints 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 Equipment 5.1.1 Cryogenic Storage Systems 5.1.1.1 Refrigerators 5.1.1.2 Ice Machines 5.1.1.3 Freezers 5.1.2 Alarm Monitoring Systems 5.1.3 Other Equipment 5.2 Media 5.2.1 Optimized Media 5.2.2 Non-optimized Media 5.3 Services 5.3.1 Human Tissue Biobanking 5.3.2 Stem Cell Biobanking 5.3.3 Cord Banking 5.3.4 DNA/RNA Biobanking 5.3.5 Other Services 5.4 Application 5.4.1 Regenerative Medicine 5.4.2 Drug Discovery 5.4.3 Disease Research 5.5 Geography 5.5.1 North America 5.5.1.1 United States 5.5.1.2 Canada 5.5.1.3 Mexico 5.5.2 Europe 5.5.2.1 Germany 5.5.2.2 United Kingdom 5.5.2.3 France 5.5.2.4 Italy 5.5.2.5 Spain 5.5.2.6 Rest of Europe 5.5.3 Asia-Pacific 5.5.3.1 China 5.5.3.2 Japan 5.5.3.3 India 5.5.3.4 Australia 5.5.3.5 South Korea 5.5.3.6 Rest of Asia-Pacific 5.5.4 Middle East & Africa 5.5.4.1 GCC 5.5.4.2 South Africa 5.5.4.3 Rest of Middle East & Africa 5.5.5 South America 5.5.5.1 Brazil 5.5.5.2 Argentina 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Atlanta Biologicals Inc. 6.1.2 Becton, Dickinson and Company 6.1.3 BioLifeSolutions Inc. 6.1.4 Chart Industries Inc. 6.1.5 Hamilton Company 6.1.6 Qiagen NV 6.1.7 Sigma-Aldrich Inc. (Merck KGaA) 6.1.8 STEMCELL Technologies Inc. 6.1.9 Thermo Fisher Scientific Inc. 6.1.10 VWR International LLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Condiments Sauces Market Size by Top Key Players 2020 Global Growth Rate by Share, Industry Segment, Future Prospect, Key Finding and Market Dynamics Forecast to 2026

Sachet Packaging Market Share and Size Analysis 2020 by Regional Demand Status, Future Growth Rate, Manufacturers, Trends by Market Dynamics and Development Scope till 2026

Animal Feed Phytases Market Share and Size Analysis 2020 by Regional Demand Status, Future Growth Rate, Manufacturers, Trends by Market Dynamics and Development Scope till 2026

Nanowires Market Size and Share by Top Players 2020 | COVID-19 Impact on Global Industry, Business Opportunities, Growth Trends and Demand till 2026

Sexually Transmitted Disease (STD) Testing Market 2020 Trends, Manufacturing Size, Growth Analysis by Share, Top Regions, Driving Factors of Manufacturers, Types and Applications Forecast to 2023

More here:
Biobanks Market Research Report 2020-2024 | Analysis by Key Regions, Manufacturing Technology and Development Forecast Industry Research.co - 3rd...

Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report – Global Forecast to 2025 – Cumulative Impact of COVID-19 – Yahoo…

By Stell Cell Research

Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market is expected to grow from USD 4,207.

New York, July 16, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913303/?utm_source=GNW 55 Million in 2019 to USD 9,109.64 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 13.73%.

Market Segmentation & Coverage: This research report categorizes the Autologous Stem Cell & Non-Stem Cell Based Therapies to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Geography, the Autologous Stem Cell & Non-Stem Cell Based Therapies Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market including Antria, Bioheart, Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Genesis Biopharma, Georgia Health Sciences University, Neostem, Opexa Therapeutics, Orgenesis, Regeneus, Regenexx, and Tengion.

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Autologous Stem Cell & Non-Stem Cell Based Therapies Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market? 4. What is the competitive strategic window for opportunities in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market? 5. What are the technology trends and regulatory frameworks in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market? 6. What are the modes and strategic moves considered suitable for entering the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market? Read the full report: https://www.reportlinker.com/p05913303/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read this article:
Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Yahoo...

→←